Associate Professor of Clinical Neuroscience at Columbia University
Pro to the question "Should Marijuana Be a Medical Option?"
"As compared with placebo, marijuana and dronabinol dose dependently increased daily caloric intake and body weight in HIV-positive marijuana smokers. All cannabinoid conditions produced significant intoxication, except for low-dose dronabinol (5 mg); the intoxication was rated positively (eg, 'good drug effect') with little evidence of discomfort and no impairment of cognitive performance. Effects of marijuana and dronabinol were comparable, except that only marijuana (3.9% THC) improved ratings of sleep.
Conclusions: These data suggest that for HIV-positive marijuana smokers, both dronabinol (at doses 8 times current recommendations) and marijuana were well tolerated and produced substantial and comparable increases in food intake."
"Dronabinol and Marijuana in HIV-Positive Marijuana Smokers: Caloric Intake, Mood, and Sleep," Journal of Acquired Immune Deficiency Syndromes, Aug. 15, 2007
Experts PhD's and JD's (lawyers) with significant post-doctoral involvement in medical marijuana issues; judges who have presided over medical marijuana cases. [Note: Experts definition varies by site.]
Involvement and Affiliations:
Associate Professor, Clinical Neuroscience, Columbia University
Co-Director, Substance Use Research Center, Columbia University
Research Scientist, New York State Psychiatric Institute
Post-doctoral fellowship, Institut National de la Santé et de la Recherche Médical (INSERM), Bordeaux, France, 1992-1994